Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
September 03, 2019 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 13, 2019 16:14 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
July 29, 2019 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors
July 16, 2019 09:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 16, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
May 21, 2019 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 16:11 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
March 19, 2019 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning
March 18, 2019 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
March 14, 2019 16:27 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 14, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
March 13, 2019 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...